Diffusion of biosimilar hemopoietic growth factors use in oncology practice: an Italian experience

Vittorio Perfetti, Simona Dalle Carbonare, Silvia Vecchio, Chiara Paglino, Simona Secondino, Michele Tringali, Paolo Pedrazzoli, Mirosa Dellagiovanna

Research output: Contribution to journalArticle

Abstract

Background: Biosimilars of hemopoietic growth factors present an important saving opportunity in oncology. However, while pharmacologists are aware of their potential benefits, biosimilars are still under-used in Italy. Improved information and guided clinical experience may help to increase the clinical acceptance of these drugs. To this aim, a collaborative educational project was set between an Hospital Oncology Unit and the Local Health Care Authority in Pavia, Italy. Methods: The project lasted 12 months. The strategy included an education-information seminar at startup, a reporting meeting at +6$+6$ months, electronic prescription monitoring and implementation of pharmacovigilance. The target was set to reach 90% of all naïve patients treated with biosimilars. Results: At the end of the study (2013), a dramatic relative increase in the prescription of biosimilar drugs was noted, with virtually 100% of new patients receiving biosimilar drugs during the last 4 months, with a positive impact on average per capita drug expenses. Active pharmacovigilance did not report any serious adverse drug reactions. An anonymous questionnaire showed that oncologists judged the experience quite positively, acquired a positive attitude toward these drugs and considered biosimilars a relevant saving opportunity, while adherence to prescription guidelines was maintained. Analysis of the year following the end of the project, 2014, showed a persistent prescription change. Conclusions: Results from this local experience suggests that specifically designed pragmatic interventions focused on information-education and monitoring may help in promoting the use and acceptance of biosimilar drugs in the real clinical setting.

Original languageEnglish
Article number3
JournalPharmacoEconomics - Italian Research Articles
Volume17
Issue number1
DOIs
Publication statusPublished - Dec 25 2015

Fingerprint

Biosimilar Pharmaceuticals
Intercellular Signaling Peptides and Proteins
Pharmacovigilance
Pharmaceutical Preparations
Italy
Prescriptions
Electronic Prescribing
Education
Hospital Units
Prescription Drugs
Drug-Related Side Effects and Adverse Reactions

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Health Policy

Cite this

Diffusion of biosimilar hemopoietic growth factors use in oncology practice : an Italian experience. / Perfetti, Vittorio; Dalle Carbonare, Simona; Vecchio, Silvia; Paglino, Chiara; Secondino, Simona; Tringali, Michele; Pedrazzoli, Paolo; Dellagiovanna, Mirosa.

In: PharmacoEconomics - Italian Research Articles, Vol. 17, No. 1, 3, 25.12.2015.

Research output: Contribution to journalArticle

@article{711bdf2e6fca48869f519e2bc6783604,
title = "Diffusion of biosimilar hemopoietic growth factors use in oncology practice: an Italian experience",
abstract = "Background: Biosimilars of hemopoietic growth factors present an important saving opportunity in oncology. However, while pharmacologists are aware of their potential benefits, biosimilars are still under-used in Italy. Improved information and guided clinical experience may help to increase the clinical acceptance of these drugs. To this aim, a collaborative educational project was set between an Hospital Oncology Unit and the Local Health Care Authority in Pavia, Italy. Methods: The project lasted 12 months. The strategy included an education-information seminar at startup, a reporting meeting at +6$+6$ months, electronic prescription monitoring and implementation of pharmacovigilance. The target was set to reach 90{\%} of all na{\"i}ve patients treated with biosimilars. Results: At the end of the study (2013), a dramatic relative increase in the prescription of biosimilar drugs was noted, with virtually 100{\%} of new patients receiving biosimilar drugs during the last 4 months, with a positive impact on average per capita drug expenses. Active pharmacovigilance did not report any serious adverse drug reactions. An anonymous questionnaire showed that oncologists judged the experience quite positively, acquired a positive attitude toward these drugs and considered biosimilars a relevant saving opportunity, while adherence to prescription guidelines was maintained. Analysis of the year following the end of the project, 2014, showed a persistent prescription change. Conclusions: Results from this local experience suggests that specifically designed pragmatic interventions focused on information-education and monitoring may help in promoting the use and acceptance of biosimilar drugs in the real clinical setting.",
author = "Vittorio Perfetti and {Dalle Carbonare}, Simona and Silvia Vecchio and Chiara Paglino and Simona Secondino and Michele Tringali and Paolo Pedrazzoli and Mirosa Dellagiovanna",
year = "2015",
month = "12",
day = "25",
doi = "10.1007/s40276-015-0026-1",
language = "English",
volume = "17",
journal = "PharmacoEconomics - Italian Research Articles",
issn = "1590-9158",
publisher = "Adis International Ltd",
number = "1",

}

TY - JOUR

T1 - Diffusion of biosimilar hemopoietic growth factors use in oncology practice

T2 - an Italian experience

AU - Perfetti, Vittorio

AU - Dalle Carbonare, Simona

AU - Vecchio, Silvia

AU - Paglino, Chiara

AU - Secondino, Simona

AU - Tringali, Michele

AU - Pedrazzoli, Paolo

AU - Dellagiovanna, Mirosa

PY - 2015/12/25

Y1 - 2015/12/25

N2 - Background: Biosimilars of hemopoietic growth factors present an important saving opportunity in oncology. However, while pharmacologists are aware of their potential benefits, biosimilars are still under-used in Italy. Improved information and guided clinical experience may help to increase the clinical acceptance of these drugs. To this aim, a collaborative educational project was set between an Hospital Oncology Unit and the Local Health Care Authority in Pavia, Italy. Methods: The project lasted 12 months. The strategy included an education-information seminar at startup, a reporting meeting at +6$+6$ months, electronic prescription monitoring and implementation of pharmacovigilance. The target was set to reach 90% of all naïve patients treated with biosimilars. Results: At the end of the study (2013), a dramatic relative increase in the prescription of biosimilar drugs was noted, with virtually 100% of new patients receiving biosimilar drugs during the last 4 months, with a positive impact on average per capita drug expenses. Active pharmacovigilance did not report any serious adverse drug reactions. An anonymous questionnaire showed that oncologists judged the experience quite positively, acquired a positive attitude toward these drugs and considered biosimilars a relevant saving opportunity, while adherence to prescription guidelines was maintained. Analysis of the year following the end of the project, 2014, showed a persistent prescription change. Conclusions: Results from this local experience suggests that specifically designed pragmatic interventions focused on information-education and monitoring may help in promoting the use and acceptance of biosimilar drugs in the real clinical setting.

AB - Background: Biosimilars of hemopoietic growth factors present an important saving opportunity in oncology. However, while pharmacologists are aware of their potential benefits, biosimilars are still under-used in Italy. Improved information and guided clinical experience may help to increase the clinical acceptance of these drugs. To this aim, a collaborative educational project was set between an Hospital Oncology Unit and the Local Health Care Authority in Pavia, Italy. Methods: The project lasted 12 months. The strategy included an education-information seminar at startup, a reporting meeting at +6$+6$ months, electronic prescription monitoring and implementation of pharmacovigilance. The target was set to reach 90% of all naïve patients treated with biosimilars. Results: At the end of the study (2013), a dramatic relative increase in the prescription of biosimilar drugs was noted, with virtually 100% of new patients receiving biosimilar drugs during the last 4 months, with a positive impact on average per capita drug expenses. Active pharmacovigilance did not report any serious adverse drug reactions. An anonymous questionnaire showed that oncologists judged the experience quite positively, acquired a positive attitude toward these drugs and considered biosimilars a relevant saving opportunity, while adherence to prescription guidelines was maintained. Analysis of the year following the end of the project, 2014, showed a persistent prescription change. Conclusions: Results from this local experience suggests that specifically designed pragmatic interventions focused on information-education and monitoring may help in promoting the use and acceptance of biosimilar drugs in the real clinical setting.

UR - http://www.scopus.com/inward/record.url?scp=84937842360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937842360&partnerID=8YFLogxK

U2 - 10.1007/s40276-015-0026-1

DO - 10.1007/s40276-015-0026-1

M3 - Article

AN - SCOPUS:84937842360

VL - 17

JO - PharmacoEconomics - Italian Research Articles

JF - PharmacoEconomics - Italian Research Articles

SN - 1590-9158

IS - 1

M1 - 3

ER -